DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

Four notable patents focus on disrupting key cancer-promoting pathways by targeting mutations in KRAS, dysregulated cyclin-dependent kinases (CDKs), and essential proteins such as EGFR, RAF1, STAT3, ...

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...

EGFR 20 外显子插入（EGFR ex20ins）突变是非小细胞肺癌（NSCLC）中除 EGFR 19 外显子缺失（19-Del）和 21 外显子 L858R 点突变（21-L858R）两大常见突变外的 EGFR 第三大突变，占所有 NSCLC ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

1Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer.